港股異動 | 南方錳業(1091.HK)高開超9% 產品售價提升 半年期利潤增長超19倍
格隆匯8月15日丨南方錳業(1091.HK)高開超9%,報1.05港元,總市值36億港元。該公司上週五盤後公佈,預計於截至2022年6月30日止6個月將取得母公司擁有人應占溢利不少於4.5億港元,相較於截至2021年6月30日止6個月期間母公司擁有人應占溢利2210萬港元增長了不少於1900%。主要因為:(1).雖然該集團的主要產品(包括電解金屬錳及電解二氧化錳)的市場價格在2022年第二季度下跌,但由於各產品在2022年第一季度觸及歷史高位,整體銷售單價同比仍取得大幅提升;及(2).該集團加蓬礦石的毛利改善因本期間提升產量及銷量增加。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.